Publication | Closed Access
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
600
Citations
29
References
2001
Year
These data suggest that donepezil's benefits extend into more advanced stages of AD than those previously investigated, with very good tolerability.
| Year | Citations | |
|---|---|---|
Page 1
Page 1